Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Dottikon Exclusive Synthesis is a premier Swiss-based contract development and manufacturing organization (CDMO) that specializes in hazardous chemistry and high-pressure reactions. The company provides a comprehensive range of services for the pharmaceutical and specialty chemical industries, focusing on the custom synthesis of active pharmaceutical ingredients (APIs) and advanced intermediates. Dottikon is globally recognized for its expertise in managing highly reactive, exothermic, and technically challenging processes such as nitrations, hydrogenations, and azide chemistry within a strict GMP environment. Operating from a single, large-scale production site in Switzerland, the company follows a one-site strategy to ensure maximum quality control and intellectual property protection. Its business model is centered on exclusive synthesis, supporting clients from initial process development through to large-scale commercial manufacturing.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Dottikon Exclusive Synthesis.